NASDAQ:CALT Calliditas Therapeutics AB (publ) (CALT) Stock Price, News & Analysis → Top 5 Tech Stocks to Buy for 2024 (From Daily Market Alerts) (Ad) Free CALT Stock Alerts $39.49 -1.92 (-4.64%) (As of 06/7/2024 ET) Add Compare Share Share Today's Range$39.22▼$40.0050-Day Range$17.55▼$41.4152-Week Range$15.25▼$41.90Volume20,026 shsAverage Volume27,302 shsMarket Capitalization$1.18 billionP/E RatioN/ADividend YieldN/APrice Target$35.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Calliditas Therapeutics AB (publ) alerts: Email Address Calliditas Therapeutics AB (publ) MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside11.4% Downside$35.00 Price TargetShort InterestHealthy0.03% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.27Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.86) to $3.64 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.45 out of 5 starsMedical Sector854th out of 904 stocksPharmaceutical Preparations Industry403rd out of 429 stocks 2.0 Analyst's Opinion Consensus RatingCalliditas Therapeutics AB (publ) has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 6 hold ratings, and no sell ratings.Amount of Analyst CoverageCalliditas Therapeutics AB (publ) has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Calliditas Therapeutics AB (publ)'s stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.03% of the outstanding shares of Calliditas Therapeutics AB (publ) have been sold short.Short Interest Ratio / Days to CoverCalliditas Therapeutics AB (publ) has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Calliditas Therapeutics AB (publ) has recently increased by 12.64%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCalliditas Therapeutics AB (publ) does not currently pay a dividend.Dividend GrowthCalliditas Therapeutics AB (publ) does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CALT. Previous Next 2.4 News and Social Media Coverage News SentimentCalliditas Therapeutics AB (publ) has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Calliditas Therapeutics AB (publ) this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for CALT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added Calliditas Therapeutics AB (publ) to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Calliditas Therapeutics AB (publ) insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.20% of the stock of Calliditas Therapeutics AB (publ) is held by insiders.Percentage Held by InstitutionsOnly 2.83% of the stock of Calliditas Therapeutics AB (publ) is held by institutions.Read more about Calliditas Therapeutics AB (publ)'s insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Calliditas Therapeutics AB (publ) are expected to grow in the coming year, from ($0.86) to $3.64 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Calliditas Therapeutics AB (publ) is -21.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Calliditas Therapeutics AB (publ) is -21.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCalliditas Therapeutics AB (publ) has a P/B Ratio of 37.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Calliditas Therapeutics AB (publ)'s valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Daily Market AlertsTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world's most powerful tech companies (including Microsoft, Intel, and Google) investing billions. And one tiny company will be the driving force behind this new tech revolution…Click below for your free report "Top 5 Tech Stocks to Buy in 2024", About Calliditas Therapeutics AB (publ) Stock (NASDAQ:CALT)Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia. It offers Nefecon (TARPEYO/Kinpeygo), an oral formulation of budesonide to reduce the loss of kidney function in adults with immunoglobulin A nephropathy. The company's lead compound is Setanaxib, a NOX inhibitor that is in Phase 2b clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for solid tumors and Alport Syndrome. Calliditas Therapeutics AB (publ) was incorporated in 2004 and is headquartered in Stockholm, Sweden.Read More CALT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CALT Stock News HeadlinesJune 7 at 11:40 AM | globenewswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AKLI, CALT, SGE on Behalf of ShareholdersJune 5 at 2:12 PM | globenewswire.comSTOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring July 18, 2024, for shares of Calliditas Therapeutics AB – CALTJune 5 at 3:40 AM | americanbankingnews.comAnalysts Set Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Target Price at $35.00June 4, 2024 | prnewswire.comSTOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces An Investigation of the Merger and its Tender Offer, Expiring July 18, 2024, for shares of Calliditas Therapeutics AB - CALTJune 2, 2024 | americanbankingnews.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Earns Neutral Rating from CitigroupMay 31, 2024 | americanbankingnews.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Sees Large Volume IncreaseMay 30, 2024 | prnewswire.comCalliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo® for the treatment of IgA nephropathyMay 30, 2024 | americanbankingnews.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Rating Lowered to Hold at Lifesci CapitalMay 30, 2024 | americanbankingnews.comStifel Nicolaus Reiterates "Hold" Rating for Calliditas Therapeutics AB (publ) (NASDAQ:CALT)May 30, 2024 | americanbankingnews.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Stock Rating Reaffirmed by Jefferies Financial GroupMay 30, 2024 | americanbankingnews.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Stock Rating Reaffirmed by HC WainwrightMay 29, 2024 | americanbankingnews.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Receives "Hold" Rating from Stifel NicolausMay 28, 2024 | finance.yahoo.comSwedish Exchange Growth Leaders: 3 Companies With Significant Insider OwnershipMay 28, 2024 | markets.businessinsider.comMaintaining Hold on Calliditas: Assessing Acquisition Fairness Amid Evolving IgAN Market DynamicsMay 28, 2024 | benzinga.comDow Dips Over 100 Points; GameStop Shares Spike higherMay 28, 2024 | benzinga.comAsahi Kasei Makes $1.1B Offer For Swedish Drugmaker Calliditas Therapeutics, Enhancing Pharma Growth StrategyMay 28, 2024 | seekingalpha.comAsahi Kasei To Pay A Fair Price For Calliditas TherapeuticsMay 28, 2024 | prnewswire.comCalliditas Therapeutics Presents Data at the 61st European Renal Association CongressMay 28, 2024 | businesswire.comCALT STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Calliditas Therapeutics AB Is Fair to ShareholdersMay 28, 2024 | finance.yahoo.comAsahi Kasei Makes $1.1 Billion Bid For Swedish Calliditas TherapeuticsMay 28, 2024 | reuters.comAsahi Kasei to buy Swedish drugmaker Calliditas for $1.1 billionMay 28, 2024 | prnewswire.comStatement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei CorporationMay 24, 2024 | markets.businessinsider.comBuy Rating Affirmed for Calliditas Therapeutics Amid Strong Growth and Expanding Market OpportunitiesMay 24, 2024 | msn.comCalliditas Therapeutics AB (publ) (NASDAQ:CALT) Q1 2024 Earnings Call TranscriptMay 23, 2024 | seekingalpha.comCalliditas Therapeutics AB (publ) 2024 Q1 - Results - Earnings Call PresentationSee More Headlines Receive CALT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Calliditas Therapeutics AB (publ) and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/23/2024Today6/08/2024Next Earnings (Estimated)8/15/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CALT CUSIPN/A CIK1795579 Webwww.calliditas.se Phone46-0-841-130-05FaxN/AEmployees217Year Founded2004Price Target and Rating Average Stock Price Target$35.00 High Stock Price Target$40.00 Low Stock Price Target$18.00 Potential Upside/Downside-11.4%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.85) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-43,960,000.00 Net Margins-40.19% Pretax Margin-37.97% Return on Equity-160.87% Return on Assets-30.64% Debt Debt-to-Equity Ratio8.46 Current Ratio2.69 Quick Ratio2.62 Sales & Book Value Annual Sales$113.78 million Price / Sales10.34 Cash FlowN/A Price / Cash FlowN/A Book Value$1.06 per share Price / Book37.25Miscellaneous Outstanding Shares29,790,000Free Float29,135,000Market Cap$1.18 billion OptionableOptionable Beta1.78 Social Links The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMs. Renee Aguiar-Lucander (Age 62)Chief Executive Officer Comp: $11.72MMr. Fredrik Johansson (Age 47)Chief Financial Officer Lars Stubberud (Age 60)Head of Technical Operations Ms. Asa Hillsten (Age 49)Head of IR & Sustainability Mr. Brian Gorman (Age 48)Group General Counsel Ms. Sandra Frithiof (Age 49)Head of Human Resources Ms. Ann-Kristin Myde BSc (Age 69)Head of Clinical Development & VP of Project Management Dr. Richard S. Philipson M.D. (Age 60)Chief Medical Officer Ms. Teona JohnsonHead of US MarketingMr. David FerraroHead of US SalesMore ExecutivesKey CompetitorsIntercept PharmaceuticalsNASDAQ:ICPTTravere TherapeuticsNASDAQ:TVTXEnanta PharmaceuticalsNASDAQ:ENTAOmerosNASDAQ:OMERNGM BiopharmaceuticalsNASDAQ:NGMView All Competitors CALT Stock Analysis - Frequently Asked Questions Should I buy or sell Calliditas Therapeutics AB (publ) stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Calliditas Therapeutics AB (publ) in the last twelve months. There are currently 6 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" CALT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CALT, but not buy additional shares or sell existing shares. View CALT analyst ratings or view top-rated stocks. What is Calliditas Therapeutics AB (publ)'s stock price target for 2024? 6 Wall Street analysts have issued 12-month price objectives for Calliditas Therapeutics AB (publ)'s shares. Their CALT share price targets range from $18.00 to $40.00. On average, they predict the company's stock price to reach $35.00 in the next year. This suggests that the stock has a possible downside of 11.4%. View analysts price targets for CALT or view top-rated stocks among Wall Street analysts. How have CALT shares performed in 2024? Calliditas Therapeutics AB (publ)'s stock was trading at $25.74 on January 1st, 2024. Since then, CALT shares have increased by 53.4% and is now trading at $39.49. View the best growth stocks for 2024 here. Are investors shorting Calliditas Therapeutics AB (publ)? Calliditas Therapeutics AB (publ) saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 9,800 shares, an increase of 12.6% from the April 30th total of 8,700 shares. Based on an average daily trading volume, of 5,500 shares, the short-interest ratio is currently 1.8 days. View Calliditas Therapeutics AB (publ)'s Short Interest. When is Calliditas Therapeutics AB (publ)'s next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 15th 2024. View our CALT earnings forecast. How were Calliditas Therapeutics AB (publ)'s earnings last quarter? Calliditas Therapeutics AB (publ) (NASDAQ:CALT) posted its earnings results on Thursday, May, 23rd. The company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by $0.74. The business earned $28.43 million during the quarter, compared to analyst estimates of $35.78 million. Calliditas Therapeutics AB (publ) had a negative trailing twelve-month return on equity of 160.87% and a negative net margin of 40.19%. What other stocks do shareholders of Calliditas Therapeutics AB (publ) own? Based on aggregate information from My MarketBeat watchlists, some companies that other Calliditas Therapeutics AB (publ) investors own include Trevena (TRVN), Advanced Micro Devices (AMD), ChromaDex (CDXC), Chimerix (CMRX), CTI BioPharma (CTIC), DRDGOLD (DRD), Forte Biosciences (FBRX). When did Calliditas Therapeutics AB (publ) IPO? Calliditas Therapeutics AB (publ) (CALT) raised $179 million in an IPO on Friday, June 5th 2020. The company issued 9,200,000 shares at $19.50 per share. Citigroup, Jefferies and Stifel acted as the underwriters for the IPO and Carnegie was co-manager. Who are Calliditas Therapeutics AB (publ)'s major shareholders? Calliditas Therapeutics AB (publ)'s stock is owned by a number of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of Calliditas Therapeutics AB (publ)? Shares of CALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CALT) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media | SponsoredThe new masters of energyAccording to one source, this new grid could soon provide energy to “one billion people in the world who don’t...Porter & Company | SponsoredWe’ve Made 1,000% … THREE Different Times in the Last Year (Here’s How)Bitcoin can and probably will hit the $1 MILLION level this decade. That’s more than 1,000% upside from the...Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calliditas Therapeutics AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Share Calliditas Therapeutics AB (publ) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
